Clinical trials
Monoclonal Gammopathy of Undetermined Significance clinical trials
Below are recruiting monoclonal gammopathy of undetermined significance clinical trials, each written for real people, not researchers. We’re tracking 24 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07209371RecruitingPhase 2
Rifaximin vs no treatment for early blood protein disorder
This study tests whether an antibiotic called rifaximin can lower the abnormal protein levels in people with MGUS (a condition that can sometimes lead to blood cancers). If it works, it might help keep MGUS from getting worse.
Seattle, WashingtonAges 18 years+ - NCT05539079Recruiting
Long-term study of MGUS and how it may change over time
This study follows people with MGUS (a blood condition that usually does not cause symptoms right away) to learn how it progresses over the long term. If you have MGUS or might have it, your results may help doctors understand risk and changes over time.
Oxford, OxfordshireAges 18 years+ - NCT04114084Recruiting
Sleep apnea study in people with MGUS or multiple myeloma
This study looks at sleep apnea (breathing pauses during sleep) in people who have MGUS or multiple myeloma. You may be asked to participate because you already need a bone marrow biopsy as part of your usual care.
Iowa City, IowaAges 18–99 - NCT05136807Recruiting
Quality of life study for people with MGUS or smoldering myeloma
This study looks at how patients feel day to day (quality of life) while they are monitored or treated for MGUS or smoldering multiple myeloma. It is designed for people who do NOT yet have “myeloma defining events” or amyloidosis, because the goal is to understand well-being in earlier disease stages.
Houston, TexasAges 18 years+ - NCT05283993Recruiting
Hospital study following people with plasma cell disorders
This is a hospital-based study that follows people with plasma cell disorders to better understand these conditions. It mainly gathers information from patients who are confirmed to have one of several related diseases.
BeijingAges Any age - NCT05361694Recruiting
Study aims to distinguish stable vs worsening early myeloma
This study looks at two different “precursor” conditions that can happen before multiple myeloma: MGUS and smoldering myeloma (SMM). Researchers want to better tell which cases are more likely to progress, using blood/urine tests and sometimes bone marrow tissue.
Miami, FloridaAges 18 years+ - NCT05640843Recruiting
Plant-based diet study for MGUS or smoldering myeloma
This trial tests whether a whole-food, plant-based eating pattern—plus supplements or placebo—can improve health outcomes in people with MGUS or smoldering multiple myeloma. You may be asked to follow specific recipes and stop certain supplements, so it helps to confirm you can stick with the plan.
Atlanta, GeorgiaAges 18 years+ - NCT05965115Recruiting
Screening study for family members of multiple myeloma patients
This trial screens first-degree relatives of people with multiple myeloma to check for early signs of the disease before symptoms. It may help doctors understand risk in families and find problems sooner if they occur.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06055894Recruiting
Plant-based diet and supplements for smoldering myeloma or MGUS
This study tests whether a plant-based diet and certain supplements can help people with smoldering multiple myeloma (SMM) or monoclonal gammopathy of undetermined significance (MGUS). Participants will learn to cook plant-based recipes and track their meals using a phone app.
Basking Ridge, New JerseyAges 18 years+ - NCT06140524RecruitingPhase 2
Study of Linvoseltamab for high-risk MGUS or smoldering myeloma
This trial tests if linvoseltamab can remove abnormal plasma cells that might turn into multiple myeloma. It is for patients with high-risk MGUS (a precancerous condition) or non-high-risk smoldering myeloma who have not yet developed active myeloma.
Baltimore, MarylandAges 18 years+ - NCT06383143Recruiting
Improving diagnosis and care for AL amyloidosis and related conditions
This study is for people who are newly diagnosed with either a very early blood condition (MGUS or smoldering myeloma) or AL amyloidosis, and who have not yet had treatment. It aims to help doctors better diagnose and manage these conditions in Italy.
BariAges 18–99 - NCT06559033Recruiting
Gene study for multiple myeloma or MGUS patients
This study looks for certain gene changes (GBA/PSAP) in people with multiple myeloma or MGUS. It aims to understand if these genes are linked to the disease, which may help guide future treatments.
RouenAges 18 years+ - NCT06644625Recruiting
CHAAMP study: MGUS screening for Black adults and relatives
This study screens for MGUS, a precursor to certain blood cancers, in people who are Black or African American, or who have a close relative with a plasma cell disorder. If MGUS is found, you may be invited to continue in the study to monitor your health.
Charlotte, North CarolinaAges 30 years+ - NCT06690593Recruiting
Gut Microbiome Study for Healthy Adults Age 45+
This study compares the gut bacteria of healthy adults (age 45+) with those who have a blood condition called monoclonal gammopathy. The goal is to see if gut bacteria patterns differ between the two groups.
Guanzhou, GuangdongAges 45 years+ - NCT06895291Recruiting
Whole body MRI for cancer patients
This study uses whole-body MRI scans to see if they help monitor or diagnose cancer better. It may be an option if your doctor has already recommended this type of scan.
Bologna, BOAges 18 years+ - NCT07214324Recruiting
Predicting blood cancer progression with genetic analysis
This study uses advanced genetic testing to see if they can predict how monoclonal gammopathies (early blood conditions that may turn into cancer) will change over time. It may help doctors understand your risk better.
BolognaAges 18 years+ - NCT01408225Recruiting
Myeloma and amyloidosis patient data and sample registry
This study collects health information and, if needed, samples from people diagnosed with certain blood disorders related to plasma cells. Sharing your information may help researchers better understand these diseases and improve future care.
Columbus, OhioAges 18 years+ - NCT02726750Recruiting
Study of early plasma cell blood conditions before myeloma
This is an observational study that follows people with early blood findings that can be linked to multiple myeloma, to understand what happens over time. It does not test a new drug for most people; instead, it tracks health, lab results, and imaging to learn who may develop myeloma.
Houston, TexasAges 18 years+ - NCT02269592Recruiting
Study blood marker changes in early, symptom-free blood cancers
This study follows people with early, “precursor” blood conditions to learn what changes in their blood or bone marrow signal progression. It may help doctors better predict outcomes and understand why some people develop symptom-causing cancer.
Boston, MassachusettsAges 18 years+ - NCT07446777Recruiting
Fasting and Mediterranean diet for multiple myeloma
This study tests whether a special diet—longer nightly fasting plus a Mediterranean eating pattern—can help people with multiple myeloma or its early stages. If you qualify, you will be randomly assigned to start the diet right away or join a waitlist group.
Miami, FloridaAges 18 years+ - NCT07057583Enrolling by invitation
Bone marrow cell study with a special carbon label
This study uses a special label (carbon 13) to track bone marrow cells in people with a pre-cancer condition called MGUS. It aims to learn how these cells work, which may help understand the condition better.
Rochester, MinnesotaAges 18 years+ - NCT06472830Enrolling by invitation
MGUS and multiple myeloma awareness screening study
This study screens adults aged 40 and older for early signs of MGUS (a benign blood condition) and multiple myeloma (a blood cancer). You'll fill out questionnaires about your health to help with early detection.
Rochester, MinnesotaAges 40 years+ - NCT06802146RecruitingEarly Phase 1
Early treatment for high-risk CCUS
This trial tests an early treatment for people with a condition called high-risk CCUS, where low blood counts and gene changes raise the risk of developing blood cancer. The goal is to see if intervening early can prevent or delay progression to leukemia or MDS.
Boston, MassachusettsAges 18 years+ - NCT07675967Recruiting
Blood Cell Changes During Cancer Treatment
This study is for people with solid tumors who are about to start chemotherapy or radiation. It looks at how these treatments affect blood cells and may help doctors understand changes in blood health over time.
Boston, MassachusettsAges 18 years+
Hear when a new Monoclonal Gammopathy of Undetermined Significance trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Monoclonal Gammopathy of Undetermined Significance trials by city
Studies with a site in or near these metro areas.
Monoclonal Gammopathy of Undetermined Significance trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for monoclonal gammopathy of undetermined significance?
- Yes. Clin2 currently lists 24 recruiting monoclonal gammopathy of undetermined significance studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a monoclonal gammopathy of undetermined significance trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a monoclonal gammopathy of undetermined significance trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.